191 related articles for article (PubMed ID: 12769632)
1. Multiple sclerosis: emerging opportunities for therapeutic intervention.
Evans CF; Shriver LP
Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):17-30. PubMed ID: 12769632
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying drugs for multiple sclerosis: current and future aspects.
Freedman MS
Expert Opin Pharmacother; 2006 Oct; 7 Suppl 1():S1-9. PubMed ID: 17020427
[TBL] [Abstract][Full Text] [Related]
3. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
4. Emerging disease modifying therapies for multiple sclerosis.
Waubant E
Expert Opin Emerg Drugs; 2003 May; 8(1):145-61. PubMed ID: 14610918
[TBL] [Abstract][Full Text] [Related]
5. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
Pender MP; Wolfe NP
Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
[TBL] [Abstract][Full Text] [Related]
6. Genomics and proteomics: role in the management of multiple sclerosis.
Kappos L; Achtnichts L; Dahlke F; Kuhle J; Naegelin Y; Sandbrink R; Lindberg RL
J Neurol; 2005 Sep; 252 Suppl 3():iii21-iii27. PubMed ID: 16170496
[TBL] [Abstract][Full Text] [Related]
7. When drugs development meets genomics.
Leung YF; Lam DS; Pang CP
Pharmacogenomics J; 2001; 1(4):237-8. PubMed ID: 11908765
[No Abstract] [Full Text] [Related]
8. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.
Galimberti D; Bresolin N; Scarpini E
Expert Rev Neurother; 2004 May; 4(3):439-53. PubMed ID: 15853541
[TBL] [Abstract][Full Text] [Related]
9. Emerging targets and treatments in amyotrophic lateral sclerosis.
Zinman L; Cudkowicz M
Lancet Neurol; 2011 May; 10(5):481-90. PubMed ID: 21511200
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
11. CNS disorders--current treatment options and the prospects for advanced therapies.
DiNunzio JC; Williams RO
Drug Dev Ind Pharm; 2008 Nov; 34(11):1141-67. PubMed ID: 18720140
[TBL] [Abstract][Full Text] [Related]
12. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.
Martinez-Forero I; Pelaez A; Villoslada P
Expert Opin Pharmacother; 2008 Dec; 9(17):3053-67. PubMed ID: 19006478
[TBL] [Abstract][Full Text] [Related]
14. [Current state of research on multiple sclerosis].
Lubina-Dabrowska N; Stepień A; Chalimoniuk M
Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Tsareva E; Kulakova O; Boyko A; Favorova O
Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
[TBL] [Abstract][Full Text] [Related]
16. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis.
Opdenakker G; Nelissen I; Van Damme J
Lancet Neurol; 2003 Dec; 2(12):747-56. PubMed ID: 14636780
[TBL] [Abstract][Full Text] [Related]
17. Current and future therapies targeting the immune system in multiple sclerosis.
Loleit V; Biberacher V; Hemmer B
Curr Pharm Biotechnol; 2014; 15(3):276-96. PubMed ID: 24938888
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Chofflon M
BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
Dolati S; Babaloo Z; Jadidi-Niaragh F; Ayromlou H; Sadreddini S; Yousefi M
Biomed Pharmacother; 2017 Feb; 86():343-353. PubMed ID: 28011382
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
